

Supplemental material


Nair et al., <https://doi.org/10.1084/jem.20180118>

Figure S1. *Irg1*^{-/-} mice are susceptible to $\Delta icl1$ *Mtb* and infection of WT-*Mtb* or *Mtb*-GFP in WT and *Irg1*^{-/-} mice and BMDMs. Related to Figs. 1 and 2. (A–E) WT and *Irg1*^{-/-} mice were infected with 100–200 CFU of aerosolized WT or isogenic $\Delta icl1$ *Mtb*. Mice were monitored for survival (A; *n* = 6–7), weight change (B; *n* = 6–7), and bacterial burden in the lung and spleen at 21 dpi (C; *n* = 8). Each point represents data from one mouse, and bars indicate median values. (D) Absolute numbers of myeloid cell populations in the lung were determined by flow cytometry at 21 dpi (*n* = 8). M ϕ , macrophages. (E) Cytokine and chemokine levels at 21 dpi in lung homogenates were measured by a Bioplex-Pro cytokine assay (*n* = 8). (F) Comparison of WT-*Mtb* and *Mtb*-GFP burden in the lung and the spleen at 21 dpi (*n* = 6–8). Each point represents data from one mouse, and bars represent the median. No statistically significant differences were detected (Mann-Whitney test). (G) CFU analysis on *Mtb*-infected (multiplicity of infection of 1) WT and *Irg1*^{-/-} BMDMs or IFN- γ pretreated WT and *Irg1*^{-/-} BMDMs at 4, 24, and 96 h postinfection. Data in panel G are representative of three independent experiments. Statistical differences were determined by log-rank test (B), Mann-Whitney test (C–E), or one-way ANOVA with Tukey's correction (F and G; *, *P* < 0.05; ***, *P* < 0.001; ns, not significant).




Figure S2. Defining cellular infiltrates in the lungs of WT and *Irg1*^{-/-} mice after *Mtb* infection and depletion of neutrophils. Related to Figs. 2 and 4. **(A)** Gating strategy for analysis of innate immune cell populations in the lungs of *Mtb*-infected WT and *Irg1*^{-/-} mice. **(B)** Absolute number of CD4⁺ T cells, CD8⁺ T cells, and B cells in the lungs of WT and *Irg1*^{-/-} mice at 21 dpi (*n* = 6). Each point represents data from one mouse, and bars represent the median. **(C)** TNF-α concentrations were measured from lungs of WT and *Irg1*^{-/-} mice by BioPlex-Pro cytokine assay at time points 10 dpi (*n* = 6), 14 dpi (*n* = 10), and 21 dpi (*n* = 6). **(D)** Mice were infected with *Mtb*-GFP. Representative histograms and flow cytometry plots for MitoSOX red⁺ and Nos2⁺ lung neutrophils in WT and *Irg1*^{-/-} mice at 21 dpi. The percentage and number of MitoSOX red⁺ and Nos2⁺ lung neutrophils in WT and *Irg1*^{-/-} mice at 21 dpi is shown. Each point represents data from one mouse, and bars represent the median. **(B–D)** Statistical differences were determined by the Mann-Whitney test (*, *P* < 0.01; **, *P* < 0.001; ***, *P* < 0.0001; ns, not significant). SSC, side scatter. **(E)** Representative flow cytometry plots from two experiments confirming the extent of neutrophil depletion in the lungs of WT and *Irg1*^{-/-} mice treated with anti-Ly6G mAb or an isotype control mAb at 21 dpi. All cells are CD45⁺CD11c: P1-CD11b^{hi} Ly6C⁺ neutrophils; P2-CD11b^{hi}Ly6C^{hi} inflammatory monocytes; and P3-CD11b^{low}Ly6C⁻ infiltrating macrophages. Numbers on gates represent frequencies of CD45⁺CD11c⁻ cells.




Figure S3. Radiosensitive hematopoietic cells promote *Irg1*-mediated responses against *Mtb* and assessment of *Irg1* exon 4 deletion in conditional knock-out mice. Related to Fig. 4. (A) Scheme for generation of bone marrow chimeric mice. (B) Survival of WT → WT, *Irg1*^{-/-} → WT, and WT → *Irg1*^{-/-} bone marrow chimeric mice infected with 100–200 CFU of aerosolized *Mtb*. The number of evaluated mice (n) is indicated in parentheses. (C) *Mtb* burden in the lung and spleen of bone marrow chimeric mice was measured at 21 dpi. (D) Absolute cell counts for WT (CD45.1) and *Irg1*^{-/-} (CD45.2) innate immune cell populations within the lungs of chimeric mice as determined by flow cytometry at 21 dpi (n = 7–8). (C–D) Each point represents data from one mouse and bars indicate median values. All data are pooled from at least two independent experiments. Statistical differences were determined by log-rank test (**, P < 0.01; B) and Mann-Whitney tests (*, P < 0.05; ***, P < 0.001; ns, not significant; C and D). Mφ, macrophages. (E–G) Cells were isolated from *Irg1*^{fl/fl} and *Irg1*^{fl/fl} Cre-expressing mice. mRNA was then extracted and reverse transcribed, and a section of the *Irg1* gene spanning the exon 4 was amplified by PCR. Nonrecombined transcript yields a 490 bp amplicon, whereas Cre recombinase-mediated excision of exon 4 results in a 290 bp amplicon. (E) Recombined *Irg1* exon 4 in bone marrow neutrophils of *Cre*⁻ *Irg1*^{fl/fl} and *Mrp8-Cre*⁺ *Irg1*^{fl/fl} mice. (F) Recombined *Irg1* exon 4 in total CD11c⁺ cells from spleens and alveolar macrophages from BAL fluid of *Cre*⁻ *Irg1*^{fl/fl} and *CD11c-Cre*⁺ *Irg1*^{fl/fl} mice. (G) Recombined *Irg1* exon 4 in bone marrow-derived neutrophils, alveolar macrophages isolated from BAL fluid, monocytes, and total CD11c⁺ cells from spleens of *Cre*⁻ *Irg1*^{fl/fl} and *LysM-Cre*⁺ *Irg1*^{fl/fl} mice.